RxDoctor Payments Data

Robert Burger, MD

Neurology · Columbia, MONPI 1053369231

Payments from drug & device makers

$68,092in general payments, 2019–2025

Across 161 payments — averaging $422.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$23K
  • AbbVie$19K
  • E.r. Squibb & Sons, L.L.C.$13K
  • Sanofi$9K
  • Cycle Pharmaceuticals Inc$1K
  • Banner Life Sciences, LLC$900
  • plus $2K from 7 others

What the payments were for

  • Consulting fees$11,49517%
  • Speaking & faculty fees$47,07469%
  • Travel & lodging$4,3566%
  • Food & beverage$4,9867%
  • Education$1810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb43$22,823
AbbVie(2 entities)39$18,939
E.r. Squibb & Sons, L.L.C.9$12,725
Sanofi33$9,463
Cycle Pharmaceuticals Inc1$1,160
Banner Life Sciences, LLC1$900
Biogen9$657
EMD Serono, Inc.6$501
Sanofi-aventis U.S. LLC6$336
Novartis9$292
TG Therapeutics, Inc.3$208
Pfizer1$76
Supernus Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,092 in reported general payments places this provider in the 80th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$20,962
Medicare patients
151
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab35$375,863
TecfideraDimethyl Fumarate23$208,208
UbrelvyUbrogepant94$104,691
VumerityDiroximel Fumarate12$104,127
FingolimodFingolimod Hcl69$68,303
Aimovig AutoinjectorErenumab-Aooe64$50,083
Emgality PenGalcanezumab-Gnlm28$26,791
QuliptaAtogepant25$25,484
Teriflunomide49$12,626
Dalfampridine ErDalfampridine19$8,030
Baclofen226$7,060
DilantinPhenytoin Sodium Extended43$6,356
Carbamazepine ErCarbamazepine22$6,103
Carbamazepine100$5,853
RelpaxEletriptan Hydrobromide11$5,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$657$312,33535 claims
AbbVieUbrelvy, Qulipta$18,939$130,175119 claims
PfizerDilantin, Relpax$76$11,66554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 381 neurology providers in Missouri.

Other neurology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →